hotspot -WSS

hotspot

author：Wikipedia 2025-09-02 22:22:10 - browse：4938

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Hospitals are piloting generative AI tools as regulators play catch

entertainment

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

A rare thyroid diagnosis led to unexpected, all

As AI regulations shape up, health tech startups beg for clarity

Stem cell treatment guidelines are released by FDA

What drug price negotiations mean for Medicare Part D

New CMS data security rules will hurt Medicare, Medicaid research

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Bright Health sells Medicare Advantage business to Molina

Weighted lottery helped low

Guidelines to prevent youth baseball injuries need more muscle

Trump surgeon general acknowledges mistakes during Covid

Sports medicine is finally prioritizing gender equality

House transparency, PBM reform bill gains bipartisan support

United colonoscopy coverage change 'may cost lives,' doctors say

'Make People Better': The CRISPR babies story you probably don't know

Guidelines to prevent youth baseball injuries need more muscle

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

hotspot

Weighted lottery helped low

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

AstraZeneca chief proposes a novel edit to the drug pricing bill

Obamacare plans could cover weight loss drugs

In 'major milestone,' FDA approves first cell therapy for solid tumors

Why Novartis is changing the name of its research labs

leisure time

hotspot

entertainment

hotspot